Whole-animal chemical screen identifies colistin as a new immunomodulator that targets conserved pathways

mBio

Volumn 5, Issue 4, 2014, Pages

  Cai, Yun ^a,b   Cao, Xiou ^a   Aballay, Alejandro ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR SKN 1; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; SIGNAL TRANSDUCTION; YERSINIA PESTIS; ANIMAL; ANIMAL MODEL; BACTERIAL INFECTIONS; DRUG EFFECTS; ENTEROCOCCUS FAECALIS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MICROARRAY ANALYSIS; MICROBIOLOGY; PRECLINICAL STUDY; PROCEDURES; STAPHYLOCOCCUS AUREUS;

ANIMALIA;

ANIMALS; BACTERIAL INFECTIONS; CAENORHABDITIS ELEGANS; COLISTIN; DRUG EVALUATION, PRECLINICAL; ENTEROCOCCUS FAECALIS; IMMUNITY, INNATE; IMMUNOMODULATION; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, ANIMAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; YERSINIA PESTIS;

EID: 84908285941     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01235-14     Document Type: Article

References (34)

1. Scannell JW, Blanckley A, Boldon H, Warrington B. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11:191-200. http://dx.doi.org/10.1038/nrd3681.
2. Coller BS, Califf RM. 2009. Traversing the valley of death: a guide to assessing prospects for translational success. Sci. Transl. Med. 1:10cm19. http://dx.doi.org/10.1126/scitranslmed.3000265.
3. Giacomotto J, Ségalat L. 2010. High-throughput screening and small animal models, where are we? Br. J. Pharmacol. 160:204-216. http://dx.doi.org/10.1111/j.1476-5381.2010.00725.x.
4. Janeway CA, Jr, Medzhitov R. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216. http://dx.doi.org/10.1146/annurev.immunol.20.083001.084359.
5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
6. Kim DH, Feinbaum R, Alloing G, Emerson FE, Garsin DA, Inoue H, Tanaka-Hino M, Hisamoto N, Matsumoto K, Tan MW, Ausubel FM. 2002. A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297:623-626. http://dx.doi.org/10.1126/science.1073759.
7. Troemel ER, Chu SW, Reinke V, Lee SS, Ausubel FM, Kim DH. 2006. p38 MAPK regulates expression of immune response genes and contributes to longevity in C. elegans. PLoS Genet. 2:e183. http://dx.doi.org/10.1371/journal.pgen.0020183.
8. Bolz DD, Tenor JL, Aballay A. 2010. A conserved PMK-1/p38 MAPK is required in Caenorhabditis elegans tissue-specific immune response to Yersinia pestis infection. J. Biol. Chem. 285:10832-10840. http://dx.doi.org/10.1074/jbc.M109.091629.
9. Sun J, Singh V, Kajino-Sakamoto R, Aballay A. 2011. Neuronal GPCR controls innate immunity by regulating noncanonical unfolded protein response genes. Science 332:729-732. http://dx.doi.org/10.1126/science.1203411.
10. Aballay A. 2013. Role of the nervous system in the control of proteostasis during innate immune activation: insights from C. elegans. PLoS Pathog. 9:e1003433. http://dx.doi.org/10.1371/journal.ppat.1003433.
11. van der Hoeven R, McCallum KC, Cruz MR, Garsin DA. 2011. Ce-Duox1/BLI-3 generated reactive oxygen species trigger protective SKN-1 activity via p38 MAPK signaling during infection in C. elegans. PLoS Pathog. 7: e1002453. http://dx.doi.org/10.1371/journal.ppat.1002453.
12. Garsin DA, Villanueva JM, Begun J, Kim DH, Sifri CD, Calderwood SB, Ruvkun G, Ausubel FM. 2003. Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science 300:1921. http://dx.doi.org/10.1126/science.1080147.
13. Irazoqui JE, Urbach JM, Ausubel FM. 2010. Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates. Nat. Rev. Immunol. 10:47-58. http://dx.doi.org/10.1038/nri2689.
14. Kerry S, TeKippe M, Gaddis NC, Aballay A. 2006. GATA transcription factor required for immunity to bacterial and fungal pathogens. PLoS One 1:e77. http://dx.doi.org/10.1371/journal.pone.0000077.
15. Hernandez E, Girardet M, Ramisse F, Vidal D, Cavallo JD. 2003. Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimicrobial agents. J. Antimicrob. Chemother. 52:1029-1031. http://dx.doi.org/10.1093/jac/dkg484.
16. Styer KL, Hopkins GW, Bartra SS, Plano GV, Frothingham R, Aballay A. 2005. Yersinia pestis kills Caenorhabditis elegans by a biofilmindependent process that involves novel virulence factors. EMBO Rep. 6:992-997. http://dx.doi.org/10.1038/sj.embor.7400516.
17. Aballay A, Ausubel FM. 2002. Caenorhabditis elegans as a host for the study of host-pathogen interactions. Curr. Opin. Microbiol. 5:97-101. http://dx.doi.org/10.1016/S1369-5274(02)00293-X.
18. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, Murray BE, Calderwood SB, Ausubel FM. 2001. A simple model host for identifying Gram-positive virulence factors. Proc. Natl. Acad. Sci. U. S. A. 98: 10892-10897. http://dx.doi.org/10.1073/pnas.191378698.
19. Bolz DD, Tenor JL, Aballay A. 2010. A conserved PMK-1/p38 MAPK is required in Caenorhabditis elegans tissue-specific immune response to Yersinia pestis infection. J. Biol. Chem. 285:10832-10840. http://dx.doi.org/10.1074/jbc.M109.091629.
20. Shivers RP, Kooistra T, Chu SW, Pagano DJ, Kim DH. 2009. Tissuespecific activities of an immune signaling module regulate physiological responses to pathogenic and nutritional bacteria in C. elegans. Cell Host Microbe 6:321-330. http://dx.doi.org/10.1016/j.chom.2009.09.001.
21. Shivers RP, Pagano DJ, Kooistra T, Richardson CE, Reddy KC, Whitney JK, Kamanzi O, Matsumoto K, Hisamoto N, Kim DH. 2010. Phosphorylation of the conserved transcription factor ATF-7 by PMK-1 p38 MAPK regulates innate immunity in Caenorhabditis elegans. PLoS Genet. 6:e1000892. http://dx.doi.org/10.1371/journal.pgen.1000892.
22. Lindblom TH, Dodd AK. 2006. Xenobiotic detoxification in the nematode Caenorhabditis elegans. J. Exp. Zool. A Comp. Exp. Biol. 305: 720-730. http://dx.doi.org/10.1002/jez.a.324.
23. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, Liu S, Oliveira RP, Baumeister R, Blackwell TK. 2008. Direct inhibition of the longevitypromoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 132: 1025-1038. http://dx.doi.org/10.1016/j.cell.2008.01.030.
24. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G. 1997. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389: 994-999. http://dx.doi.org/10.1038/40194.
25. Singh V, Aballay A. 2006. Heat-shock transcription factor (HSF)-1 pathway required for Caenorhabditis elegans immunity. Proc. Natl. Acad. Sci. U. S. A. 103:13092-13097. http://dx.doi.org/10.1073/pnas.0604050103.
26. Tauber SC, Nau R. 2008. Immunomodulatory properties of antibiotics. Curr. Mol. Pharmacol. 1:68-79. http://dx.doi.org/10.2174/1874467210801010068.
27. Rubin BK, Henke MO. 2004. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125(2 Suppl):70S-78S. http://dx.doi.org/10.1378/chest.125.2_suppl.70S.
28. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, Study, Macrolide Group. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749-1756. http://dx.doi.org/10.1001/jama.290.13.1749
29. Melo JA, Ruvkun G. 2012. Inactivation of conserved C. elegans genes engages pathogen-and xenobiotic-associated defenses. Cell 149:452-466. http://dx.doi.org/10.1016/j.cell.2012.02.050.
30. Brenner S. 1974. The genetics of Caenorhabditis elegans. Genetics 77:71-94.
31. Tan MW, Rahme LG, Sternberg JA, Tompkins RG, Ausubel FM. 1999. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc. Natl. Acad. Sci. U. S. A. 96: 2408-2413. http://dx.doi.org/10.1073/pnas.96.5.2408.
32. Une T, Brubaker RR. 1984. In vivo comparison of avirulent Vwa-and Pgm-or Pstr phenotypes of yersiniae. Infect. Immun. 43:895-900.
33. Murray BE, Singh KV, Ross RP, Heath JD, Dunny GM, Weinstock GM. 1993. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol. 175:5216-5223.
34. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.